Does dapagliflozin change heart function as detected by ultrasound in patients with heart failure?

Not Applicable

Completed

• Conditions: Circulatory System; Heart failure and reduced ejection fraction

• Registration Number: ISRCTN95382621
• Lead Sponsor: Mouloud Mammeri University of Tizi-Ouzou

Brief Summary

2022 Results article in https://pubmed.ncbi.nlm.nih.gov/36096950/ (added 09/05/2023)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2022-03-31
• Study Start: 2022-07-06
• Last Update Posted: 22 May 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 43

Inclusion Criteria

Patients with HFrEF<40% in NYHA stage II to IV, who presented to our department during the recruitment period

Exclusion Criteria

Type 1 diabetes

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Heart failure functional classification assessed using NYHA stage at the first visit<br>2. Hospitalization rate recorded in our HF hospital registry at the end of the study<br>3. Ejection fraction (EF) measured by an echocardiogram (ECG) at the first visit, 3 months, and at 7 months (5-8 months) follow-up

Secondary Outcome Measures

Name	Time	Method
1. Mean left ventricular dysfunction (LVd) measured by an echocardiogram (ECG) at the first visit, 3 months, and at 7 months (5-8 months) follow-up<br>2. Systolic pulmonary pressure (sPAP) measured by an ECG at the first visit, 3 months, and at 7 months (5-8 months) follow-up<br>3. Mean longitudinal Strain measured by ECG at the first visit, 3 months, and at 7 months (5-8 months) follow-up<br>4. Urinary tract infection assessed by interrogation (presence of burning urination) and urine strip (Labstix) at each consultation (at the first visit, 3 months, and at 7 months (5-8 months) follow-up) and if necessary cytobacteriological urine examination (in the case of burning urination)